Impressive Q1 2024 Results for Henlius: Revenue Surges to 1.349 Billion Yuan, Hanqu Leads with Sales of ￥671 Million

Henlius, a leading pharmaceutical company, has reported impressive financial results for the first quarter of 2024. With a strong focus on patient-centric commercial strategies and leveraging their core products, Henlius achieved a remarkable revenue of 1.349 billion yuan. Notably, Hanqu, one of their flagship products, drove sales with an outstanding performance of 671 million yuan in the same period.

Henlius, a renowned pharmaceutical company, recently announced its financial results for the first quarter of 2024. The company continued its upward trajectory, with substantial growth in revenue and significant contributions from its core product portfolio. Among these products, Hanqu stood out with remarkable sales, solidifying Henlius's position in the market.

During the first quarter of 2024, Henlius achieved a robust revenue figure of 1.349 billion yuan, highlighting its consistent performance in delivering value to stakeholders. This achievement follows the company's successful profitability in 2023, demonstrating its ability to capitalize on its existing advantages and execute patient-centric commercial strategies effectively.

Hanqu, a flagship product in Henlius's oncology portfolio, played a pivotal role in driving the company's revenue growth. Hanqu, also known as Qu Tutuzumab (HERCESSI™ in the United States and Zercepac® in Europe), is used for the treatment of HER2-positive breast cancer and gastric cancer. With its unique differentiators such as dual specifications of 150mg and 60mg and the absence of preservatives, Hanqu has gained widespread clinical recognition and application.

The success of Hanqu can be attributed not only to its differentiating features but also to Henlius's strategic approach. The company has established a strong sales network for Hanqu, comprising a dedicated commercial team of approximately 600 professionals, covering nearly 3,700 hospitals across six major sales regions in China. Hanqu has also gained regulatory approvals and market presence in more than 40 countries and regions, including the United States, European Union, and Brazil, making it a prominent "Made in China" biosimilar drug on the global stage.

Furthermore, Hanqu's inclusion in national healthcare systems in countries such as the United Kingdom, France, and Germany has significantly enhanced its accessibility, ensuring that more patients can benefit from this innovative therapy. Henlius's efforts to expand Hanqu's global footprint have resulted in successful market authorizations in countries like Indonesia, and submissions for market approvals in Thailand, Singapore, and Malaysia are already underway.

In addition to Hanqu, Henlius's innovative product portfolio features another noteworthy product called Hans Zhuang® (SLR-D1), which is the first-in-class anti-PD-1 monoclonal antibody for the frontline treatment of small cell lung cancer (SCLC). Since its successful launch in 2022, Hans Zhuang® has received regulatory approvals for multiple indications, benefiting over 60,000 Chinese patients. The product's registration application for the first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC) has also been accepted by the National Medical Products Administration (NMPA).

Henlius has strategically positioned itself in the global market by expanding the reach of its products. With a comprehensive commercialization team of approximately 580 professionals, the company has successfully secured tenders and market access in all provinces and cities in China, significantly improving product availability. Moreover, Henlius has initiated global authorization efforts for Hans Zhuang®, covering more than 70 countries and regions, including the United States, Europe, Southeast Asia, the Middle East, and North Africa.

Looking forward, Henlius remains committed to its patient-centric approach and aims to deepen its differentiation through innovative research and development. The company will continue its comprehensive commercial capabilities and expand its global market presence, solidifying its position as an "integrated research, development, production, and sales" platform. With a focus on high-quality development, Henlius is poised to enter a new phase of growth, benefiting patients worldwide.

In conclusion, Henlius's impressive financial results for Q1 2024 reflect its commitment to patient-centric strategies and the success of its core products. With substantial revenue growth and exceptional sales performance by Hanqu, Henlius has established itself as a key player in the pharmaceutical industry, both domestically and internationally. As the company continues to expand its global presence and drive innovation, it is poised for a promising future in delivering high-quality healthcare solutions.